VSTM2L and rectal cancer: A higher mortality rate was observed in high-risk CIMP patients with elevated expression of prognostic genes including VSTM2L (Zeng et al., 2020); and in rectal cancer patients receiving preoperative chemoradiotherapy, high VSTM2L expression was correlated with poor therapeutic response and adverse clinical outcomes (Liu et al., 2021).